Dermira Inc.’s third positive phase III trial with Cimzia (certolizumab pegol) in moderate to severe psoriasis turned up “market-leading type” results at the 400-mg dose, the firm’s chief development officer, Luis Peña, told BioWorld Today, and enables a regulatory filing in Europe.